Currently out of the existing stock ratings of Steve Scala, 52 are a BUY (76.47%), 16 are a HOLD (23.53%).

Steve Scala

Work Performance Price Targets & Ratings Chart

Analyst Steve Scala, currently employed at KEYBANK, carries an average stock price target met ratio of 75.89% that have a potential upside of 38.53% achieved within 782 days. Previously, Steve Scala worked at TD COWEN.

Steve Scala’s has documented 148 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ABBV, AbbVie at 07-Oct-2024.

Wall Street Analyst Steve Scala

Analyst best performing recommendations are on LLY (ELI LILLY AND COMPANY).
The best stock recommendation documented was for LLY (ELI LILLY AND COMPANY) at 4/24/2018. The price target of $95 was fulfilled within 114 days with a profit of $22.97 (31.89%) receiving and performance score of 2.8.

Average potential price target upside

of $39.71 (25.82%) on LLY (ELI LILLY AND COMPANY).
of $31.5 (49.33%) on NVS (NOVARTIS AG ADR).
of $31.04 (43.67%) on ABBV (ABBVIE).

ABBV AbbVie AZN AstraZeneca PLC ADR BMY Bristol-Myers Squibb Company ELAN Elanco Animal Health GSK GlaxoSmithKline PLC ADR LLY Eli Lilly and Company MRK Merck mpany NVS Novartis AG ADR PFE Pfizer EQRX EQRx ZTS Zoetis NVO Novo Nordisk A/S RHHBY Roche Holding Ltd ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Geoff Meacham (CITI)